Clinical burden, treatment, and disease control in patients with chronic spontaneous urticaria
Of patients with CSU who were prescribed treatment, more than 50% experienced uncontrolled CSU, which was associated with increased HCRU and health care costs.
Authors
- Arthur Voegel
- Gil Yosipovitch (ORCID: https://orcid.org/0000-0001-6303-1822)
- James Signorovitch (ORCID: https://orcid.org/0000-0002-4067-8962)
- Jason Doran (ORCID: https://orcid.org/0000-0002-5501-9433)
- Marc A. Riedl (ORCID: https://orcid.org/0000-0003-3460-1544)
- Merin Kuruvilla (ORCID: https://orcid.org/0000-0002-2668-4418)
- Irina Pivneva (ORCID: https://orcid.org/0000-0003-1101-5200)
- Jonathan Rodrigues (ORCID: https://orcid.org/0000-0003-2744-3509)
- Tara C. Raftery
- Dhaval Patil
Institutions
- Novartis (Switzerland) (CH)
- University of Miami (US)
- University of California San Diego (US)
- Novartis (United States) (US)
- Group for Research in Decision Analysis (CA)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Novartis (Ireland) (IE)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Annals of Allergy Asthma & Immunology
- Published
- 2024-12-16
- DOI
- https://doi.org/10.1016/j.anai.2024.12.008
- Citations
- 7
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 3.29
Funders
- Novartis
- Novartis Pharmaceuticals Corporation